Delinia
Clinical-stage biotechnology company developing selective IL-2 therapies to restore immune balance in patients with autoimmune diseases by preferentially activating regulatory T cells.
Notes
Delinia is a clinical-stage biotechnology company based in Watertown, Massachusetts, focused on developing next-generation immunotherapies for autoimmune diseases. The company's approach centers on selectively modulating the IL-2 pathway to restore immune balance by preferentially activating regulatory T cells (Tregs) while avoiding activation of effector T cells.
The company's lead program, DEL-106, is a long-acting, selective IL-2 agonist designed to expand and activate Tregs for the treatment of autoimmune diseases. This approach represents a potentially transformative therapy for conditions where immune dysregulation plays a central role.
Delinia was acquired by Roivant Sciences in 2023 for up to $325 million, becoming part of Roivant's portfolio of healthcare companies.
Team
- Jens Loennberg - Former CEO (prior to acquisition)
- Andrew Bhak - Former Chief Scientific Officer
Additional Research Findings
- Portfolio company of Sofinnova Partners
- Founded in 2020
- Acquired by Roivant Sciences in 2023 for up to $325 million
- Focus on selective IL-2 therapies
- Lead program: DEL-106, a selective IL-2 agonist
- Target: Regulatory T cell activation for autoimmune diseases
- Based in Watertown, Massachusetts
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |